Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial
- DOI
- 10.1007/s40261-023-01252-z
- Published
- 2023-04
- Container
- Clinical Drug Investigation
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s40261-023-01252-z,
title = {Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial},
author = {Geert D’Haens and Walter Reinisch and Stefan Schreiber and Fraser Cummings and Peter M. Irving and Byong Duk Ye and Dong-Hyeon Kim and SangWook Yoon and Shomron Ben-Horin},
year = {2023},
journal = {Clinical Drug Investigation},
doi = {10.1007/s40261-023-01252-z},
url = {https://doi.org/10.1007/s40261-023-01252-z}
}RIS
TY - JOUR TI - Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial AU - Geert D’Haens AU - Walter Reinisch AU - Stefan Schreiber AU - Fraser Cummings AU - Peter M. Irving AU - Byong Duk Ye AU - Dong-Hyeon Kim AU - SangWook Yoon AU - Shomron Ben-Horin PY - 2023 JO - Clinical Drug Investigation DO - 10.1007/s40261-023-01252-z UR - https://doi.org/10.1007/s40261-023-01252-z ER -
APA
D’Haens, G., Reinisch, W., Schreiber, S., Cummings, F., Irving, P. M., Ye, B. D., Kim, D., Yoon, S., & Ben-Horin, S. (2023). Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial. Clinical Drug Investigation. https://doi.org/10.1007/s40261-023-01252-z
Source records
- crossref · retrieved 2026-09-26T12:31:57.139Z